1. Search Result
Search Result
Results for "

β-receptor

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

4

Peptides

1

Inhibitory Antibodies

2

Natural
Products

30

Recombinant Proteins

2

Isotope-Labeled Compounds

3

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100935

    CL 263780; (±)-2-Amino-5-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]benzonitrile

    Adrenergic Receptor Metabolic Disease
    Cimaterol (CL 263780) is a β-adrenergic agonist on energy metabolism in ob/ob mice . The Kd for Cimaterol binding to the L6 β-receptor is 26 nM which is compatible with its EC50 for the stimulation of protein synthesis (approx 5 nM) .
    Cimaterol
  • HY-125703

    Estrogen Receptor/ERR Apoptosis Infection Inflammation/Immunology Endocrinology Cancer
    Ferutinin, a natural terpenoid compound, is an estrogen receptor ERα agonist and estrogen ERβ-receptor agonist/antagonist with IC50s of 33.1 nM and 180.5 nM, respectively. Ferutinin acts as an electrogenic Ca 2+-ionophore that increases calcium permeability of lipid bilayer membranes, mitochondria. Ferutinin possesses estrogenic, antitumor, antibacterial and antiinflammatory activities .
    Ferutinin
  • HY-B0437
    Sotalol hydrochloride
    2 Publications Verification

    MJ 1999

    Adrenergic Receptor Potassium Channel Cardiovascular Disease Neurological Disease
    Sotalol hydrochloride (MJ 1999) is an orally active, non-selective β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .
    Sotalol hydrochloride
  • HY-12704
    ITD-1
    5 Publications Verification

    TGF-β Receptor Cardiovascular Disease
    ITD-1 is the first selective TGFβ receptor inhibitor with an IC50 of 460 nM.
    ITD-1
  • HY-108533

    RAR/RXR Cancer
    CD2314 is a potent and selective RARβ receptor agonist with a Kd of 195 nM in S91 melanoma cells .
    CD2314
  • HY-12075
    LY2109761
    45+ Cited Publications

    TGF-β Receptor Autophagy Cancer
    LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with Kis of 38 nM and 300 nM, respectively.
    LY2109761
  • HY-13226
    Galunisertib
    40+ Cited Publications

    LY2157299

    TGF-β Receptor Cancer
    Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
    Galunisertib
  • HY-103196

    Adrenergic Receptor Potassium Channel Cardiovascular Disease Neurological Disease
    Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .
    Sotalol
  • HY-153535

    Thyroid Hormone Receptor Metabolic Disease
    THRβ receptor agonist-1 is a THRβ receptor agonist .
    THRβ receptor agonist-1
  • HY-13226A

    TGF-β Receptor Cancer
    Galunisertib monohydrate is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
    Galunisertib monohydrate
  • HY-N2092

    Bacterial Infection Cancer
    Atractylodinol, an antimicrobial, is a PRRSV (porcine reproductive and respiratory syndrome virus) inhibitor. Atractylodinol inhibits TGF-β receptor I recycling by binding to vimentin (KD of 454 nM) and inducing the formation of filamentous aggregates .
    Atractylodinol
  • HY-114192

    TGF-β Receptor Cancer
    TGFβRI-IN-1 is an oral active and selective TGFβ receptor type I (TGFβRI) kinase inhibitor, with IC50 values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively .
    TGFβRI-IN-1
  • HY-156679

    Thyroid Hormone Receptor Neurological Disease
    VK-0214 is an agonist for thyroid beta receptor (TRβ), which ameliorates the X-linked adrenoleukodystrophy (X-ALD), through activation of ABCD2 expression and reduction of very long chain fatty acids (VLCFA) accumulation .
    VK-0214
  • HY-111014

    Calcium Channel Cardiovascular Disease
    VK-II-36 is a carvedilol analog that suppresses sarcoplasmic reticulum Ca 2+release but does not block the β-receptor.VK-II-36 inhibits triggered activities evoked by both early and delayed after depolarizations .
    VK-II-36
  • HY-160237

    TGF-β Receptor Cancer
    HYL001 (compund 338) is a potent inhibitor of TGFβ receptor 1 (ALK5) that is approximately 9 times more potent than the structurally related compound Galunisertib (HY-13226) and is able to eliminate liver metastases established in mice .
    HYL001
  • HY-103021
    LY3200882
    5+ Cited Publications

    TGF-β Receptor Inflammation/Immunology Cancer
    LY3200882 is a potent, highly selective, ATP-competitive and orally active TGF-β receptor type 1 (ALK5) inhibitor with an IC50 of 38.2 nM. LY3200882 inhibits various pro-tumorigenic activities and is also used as an immune modulatory agent .
    LY3200882
  • HY-101309A

    Others Cancer
    5-(Nonyloxy)tryptamine oxalate, a high-affinity agonist for the 5-HTIDβ receptor, with an ED50 value of 68 nM. 5-(Nonyloxy)tryptamine oxalate, exhibits antitumor growth activity in vivo and enhances the ability of T cells to target tumor cells .
    5-(Nonyloxy)tryptamine oxalate
  • HY-10431G

    TGF-β Receptor Neurological Disease Cancer
    SB-431542 (GMP) is SB-431542 (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI) in SMAD signaling .
    SB-431542
  • HY-P10414

    KP1 (human)

    TGF-beta/Smad p38 MAPK Inflammation/Immunology
    Klotho-derived peptide 1 (KP1 human) blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .
    Klotho-derived peptide 1
  • HY-B0437AS

    MJ 1999-d6 hydrochloride

    Adrenergic Receptor Potassium Channel Cardiovascular Disease Endocrinology
    Sotalol-d6 (hydrochloride) is a deuterium labeled Sotalol hydrochloride. Sotalol hydrochloride is an orally active, non-selective competitive β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels[1][2].
    Sotalol-d6 hydrochloride
  • HY-P10414A

    KP1 (human) hydrochloride

    TGF-beta/Smad p38 MAPK Inflammation/Immunology
    Klotho-derived peptide 1 (KP1 human) hydrochloride blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .
    Klotho-derived peptide 1 hydrochloride
  • HY-13521
    SB-505124
    15+ Cited Publications

    TGF-β Receptor Cancer
    SB-505124 is a selective inhibitor of TGF-β Receptor type I receptors (ALK4, ALK5, ALK7), with IC50s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.
    SB-505124
  • HY-13521A
    SB-505124 hydrochloride
    15+ Cited Publications

    TGF-β Receptor Cancer
    SB-505124 hydrochloride is a selective inhibitor of?TGF-β Receptor type I receptor (ALK4, ALK5, ALK7), with?IC50s?of 129 nM and 47 nM for?ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.
    SB-505124 hydrochloride
  • HY-B0437S

    MJ 1999-d6

    Isotope-Labeled Compounds Adrenergic Receptor Potassium Channel Cardiovascular Disease Neurological Disease
    Sotalol-d6 is the deuterium labeled Sotalol. Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent[1][2][3][4].
    Sotalol-d6
  • HY-107397
    Ch55
    2 Publications Verification

    RAR/RXR Cancer
    Ch55 is a potent synthetic retinoid. Ch55 binds to RAR-α and RAR-β receptors with high affinity. Ch55 displays low affinity for cellular retinoic acid binding protein (CRABP). Ch55 is a potent inducer of the differentiation of HL60 cells with an EC50 of 200 nM. Ch55 can be used for cancer research .
    Ch55
  • HY-146780

    TGF-β Receptor Cancer
    TGFβRI-IN-4 is a highly potent and orally active TGFβ receptor type I (TGFβRI) inhibitor, with IC50s of 44 nM and 42.5 nM for ALK5 and NIH3T3. TGFβRI-IN-4 can suppress tumor growth and tumor weight in tumor xenograft model .
    TGFβRI-IN-4
  • HY-W684904

    TGF-β Receptor Cancer
    LY550410 is a small-molecule ATP-competitive inhibitor against type I TGF-β receptor kinase, which contains heteroaryl rings for potent binding to the kinase-domain active site. LY550410 modulates TGF-β signalling, thereby regulates gene expression and ultimately cell growth. LY550410 is promising for research of cancers .
    LY550410
  • HY-13012
    RepSox
    15+ Cited Publications

    E-616452; SJN 2511

    Organoid TGF-β Receptor Metabolic Disease
    RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .
    RepSox
  • HY-B0203
    Nebivolol
    3 Publications Verification

    R 065824

    Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
    Nebivolol
  • HY-B0203A
    Nebivolol hydrochloride
    3 Publications Verification

    R 065824 hydrochloride

    Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
    Nebivolol hydrochloride
  • HY-123984

    NF-κB Metabolic Disease
    LTβR-IN-1 is a potent, selective lymphotoxin β receptor (LTβR) inhibitor. LTβR-IN-1 also selectively inhibits the nuclear translocation of p52 depended on TNF12A, instead of the nuclear translocation of p65 mediated by TNF-α receptor. LTβR-IN-1 regulates the NF-kB signaling pathway IN a ligand-independent manner .
    LTβR-IN-1
  • HY-13894
    Tyrphostin AG1296
    1 Publications Verification

    AG1296

    PDGFR c-Kit FLT3 Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Tyrphostin AG1296 is a potent and selective inhibitor of platelet-derived growth factor receptor (PDGFR), with an IC50 of 0.8 μM. Tyrphostin AG1296 inhibits signaling of human PDGF α- and β-receptors as well as of the related stem cell factor receptor (c-Kit). Tyrphostin AG1296 is also a potent inhibitor of FLT3, with an IC50 in the micromolar range .
    Tyrphostin AG1296
  • HY-108628
    SU16f
    1 Publications Verification

    PDGFR Cancer
    SU16f is a potent and selective PDGFRβ inhibitor with IC50s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, PDGFR1, PDGFR2, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .
    SU16f
  • HY-P1542

    Catostomus urotensin I

    CRFR Cardiovascular Disease Endocrinology
    Urotensin I (Catostomus urotensin I), a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF receptors in CHO cells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF and mCRF receptors, respectively .
    Urotensin I
  • HY-W105318

    PBP

    TGF-beta/Smad Apoptosis Cancer
    Pentabromophenol (PBP) is a brominated flame retardant (BFR) widely used in various consumer products to reduce the flammability of materials used in different utility items. Pentabromophenol can accelerate the degradation of transforming growth factor-β (TGF-β) receptors by promoting clathrin-mediated endocytosis, thereby inhibiting the TGF-β signaling pathway. Additionally, Pentabromophenol can also induce apoptosis in peripheral blood mononuclear cells (PBMCs) .
    Pentabromophenol
  • HY-P1542B

    Catostomus urotensin I TFA

    CRFR Cardiovascular Disease Endocrinology
    Urotensin I (Catostomus urotensin I) TFA, a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF receptors in CHO cells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF and mCRF receptors, respectively .
    Urotensin I TFA
  • HY-B0203AR

    R 065824 hydrochloride (Standard)

    Adrenergic Receptor Cardiovascular Disease Endocrinology
    Nebivolol (hydrochloride) (Standard) is the analytical standard of Nebivolol (hydrochloride). This product is intended for research and analytical applications. Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
    Nebivolol hydrochloride (Standard)
  • HY-10431
    SB-431542
    Maximum Cited Publications
    191 Publications Verification

    Organoid TGF-β Receptor Apoptosis Cancer
    SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .
    SB-431542
  • HY-B0432
    Propafenone
    1 Publications Verification

    SA-79

    Sodium Channel Adrenergic Receptor Potassium Channel Cardiovascular Disease Cancer
    Propafenone (SA-79), a sodium-channel blocker, acts an antiarrhythmic agent. Propafenone also has high affinity for the β receptor (IC50=32 nM) . Propafenone blocks the transient outward current (Ito) and the sustained delayed rectifier K current (Isus) with IC50 values of 4.9 μm and 8.6 μm, respectively . Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction and induce apoptosis .
    Propafenone
  • HY-W063968
    RO8191
    10+ Cited Publications

    CDM-3008; RO4948191

    IFNAR JAK STAT HCV HBV Infection
    RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon . RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity .
    RO8191
  • HY-B0432R

    Sodium Channel Adrenergic Receptor Potassium Channel Cardiovascular Disease Cancer
    Propafenone (Standard) is the analytical standard of Propafenone. This product is intended for research and analytical applications. Propafenone (SA-79), a sodium-channel blocker, acts an antiarrhythmic agent. Propafenone also has high affinity for the β receptor (IC50=32 nM) . Propafenone blocks the transient outward current (Ito) and the sustained delayed rectifier K current (Isus) with IC50 values of 4.9 μm and 8.6 μm, respectively . Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction and induce apoptosis .
    Propafenone (Standard)
  • HY-10431R

    Apoptosis TGF-β Receptor Organoid Cancer
    SB-431542 (Standard) is the analytical standard of SB-431542. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .
    SB-431542 (Standard)
  • HY-112417

    PDGFR FLT3 Apoptosis Akt PERK Bcl-2 Family Cardiovascular Disease Cancer
    Ki11502 is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGF β/α receptors with IC50 values less than 10 nM. Ki11502 selectively inhibits PDGF β receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Ki11502 can induce Apoptosis) and exhibits profound antiproliferative effects on select subsets of leukemia, including those with Imatinib (HY-15463) resistant mutations. Ki11502 is highly suitable for studying the role of PDGF in vascular diseases, particularly the role of proteoglycans in atherosclerosis .
    Ki11502
  • HY-161925

    Others Neurological Disease Inflammation/Immunology
    sTGFBR3 antagonist 1 (Compound p24) is an antagonist for soluble transforming growth factor beta receptor 3 (sTGFBR3), thus activates TGF-β signaling pathway, and inhibits IκBα/NF-κB signaling pathway. sTGFBR3 antagonist 1 inhibits NO-release in LPS (HY-D1056) -induced BV2 cells with an IC50 of 0.52 μM. sTGFBR3 antagonist 1 exhibits anti-inflammatory and neuroprotective activities with blood brain barrier (BBB) permeability. sTGFBR3 antagonist 1 can be used in Alzheimer’s Disease research .
    sTGFBR3 antagonist 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: